ShockWave Medical, Inc. (NASDAQ:SWAV) is expected to report second quarter earnings results, after market close, on Tuesday 11th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.62 per share.
Looking ahead, the full year loss are expected at $ 2.31 per share on the revenues of $ 57.72 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 74.00 million ~ $ 77.00 million
Click Here For More Historical Outlooks Of ShockWave Medical, Inc.
Previous Quarter Performance
ShockWave Medical, Inc. recorded loss for the first quarter of $ 0.59 per share, from the revenue of $ 15.20 million. The quarterly revenues extended 167.14 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.49 per share from $ 14.17 million in revenue. The bottom line results missed street analysts by $ 0.1 or 20.41 percent, at the same time, top line results outshined analysts by $ 1.03 million or 7.27 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of ShockWave Medical, Inc.
Stock Performance
According to the previous trading day, closing price of SWAV was $ 51.50, representing a 133.98 % increase from the 52 week low of $ 22.01 and a 3.43 % decrease over the 52 week high of $ 53.33.
The company has a market capital of $ 1.74 billion and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”SWAV” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
ShockWave Medical, Inc. will be hosting a conference call at 4:30 PM eastern time on 11th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.shockwavemedical.com
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors.
